[PDF] Top 20 Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
Has 10000 "Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis" found on our website. Below are the top 20 most common "Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis".
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis
... We found that IHD and anxiety were strongly associated with a decreased likelihood of initiating a DMT. Other conditions, such as hyperlipidemia, chronic lung diseases, and bipolar disorder, also ex- hibited similar ... See full document
10
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study
... DMD therapy on pregnancy outcome. Potential mechanisms of adverse effects may be due to direct mutagenic actions, impairment of spermatogenesis, or the transfer of chemicals via semen ...direct ... See full document
8
Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
... the use of these instruments in a patient sample from the middle ...to use Arabic versions of the PHQ9 and GAD7 and were still unable to find a significant relationship between Table 2 Univariate analysis ... See full document
6
A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis
... Remitting Multiple Sclerosis; DMTs: Disease Modifying Therapies; ECTRIMS: European Committee for Treatment and Research in Multiple Sclerosis; EDSS: Expanded Disability Status ... See full document
9
FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value
... the use of glatiramer acetate are comparable to those for interferon beta and it is appropriate to consider it for treatment in any patient with RRMS (Goodin et ...the disease- modifying agents, the ... See full document
11
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
... the effects of high-dose high-frequency interferon beta 1a (IFNβ1a) on brain parenchymal fraction (BPF) loss can be deduced from the CARE-MS-I and CARE-MS-II ...successful disease-modifying ... See full document
10
Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
... in disease progression, reduction or prolongation of time to long-term dis- ability, and reduction in new magnetic resonance imaging lesions, were not discussed with ...MS therapy (23% indicated taking a ... See full document
9
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
... In the article “High prevalence of neutralizing antibodies after long-term botulinum neu- rotoxin therapy,” Albrecht et al. investigated the prevalence of neutralizing antibodies (NAbs) against botulinum ... See full document
7
Disease-modifying therapies in relapsing–remitting multiple sclerosis
... its use for MS has not been well ...side effects, including alopecia, nausea, vomiting, and amenorrhea occur at high frequency, and there is also evidence to suggest adverse effects appearing after ... See full document
9
Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
... for use in Canada in 1995, and until this time, the only treatment for MS was high-dose corticosteroids to treat ...severe disease compared to those who were treated when DMTs first became ...severe ... See full document
9
Applying the theory of planned behaviour to multiple sclerosis patients’ decisions on disease modifying therapy – questionnaire concept and validation
... Modeling behavioural decisions in terms of TPB con- forms to basic assumptions of patient empowerment, since it takes into account the social situation (subjective social norm) and self-efficacy (control beliefs) as well ... See full document
9
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosisReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
... In the article “High prevalence of neutralizing antibodies after long-term botulinum neu- rotoxin therapy,” Albrecht et al. investigated the prevalence of neutralizing antibodies (NAbs) against botulinum ... See full document
19
TERIFLUNOMIDE: A NOVEL ORAL DISEASE-MODIFYING AGENT UNDER INVESTIGATION FOR THE TREATMENT OF MULTIPLE SCLEROSIS
... oral disease-modifying ...oral therapy are likely reflected in the relatively low discontinuation ...the use of other immunosuppressive agents in individuals with breakthrough disease ... See full document
6
Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients
... GA therapy, at least in the 1 year following treatment ...issues, comorbidities, pregnancy), while in the case of disease reactivation escalation approaches appear more appropriate [15, ... See full document
9
The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis
... effective therapy. This has led to a re- consideration of the possible use of medications during pregnancy, to protect the health of the ...these effects [70, ...the use of natalizumab ... See full document
27
Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment
... side effects used in the study is not necessarily suited to categorize side effects in daily practice, semistructured interviews with patients and MS physicians revealed that, since severity of side ... See full document
12
Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis
... Crohn disease (n ⫽ 1), and myasthenia gravis (n ⫽ 1), they were excluded from MRI ...any comorbidities, were found, no comparison of secondary MRI outcomes was performed for these comorbidities ... See full document
7
Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
... relapsing-remitting multiple sclerosis (RRMS), and the most commonly- used drugs as ...of disease-modifying drugs, especially INF-β, could affect and enhance this ...the use of GA over ... See full document
8
Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients
... Multiple sclerosis (MS) is a leading cause of non-trau- matic neurological disability for young adults ...relapsing-remitting multiple sclerosis (RRMS) and ex- perience clearly defined ... See full document
11
Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study
... clinical outcomes for existing disease states are major areas of interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and ... See full document
5
Related subjects